Evidence map›Paper›PMID 34430354›Full record

ArticleTranslational lung cancer research2021

Systemic immune-inflammation index is a stage-dependent prognostic factor in patients with operable non-small cell lung cancer.

Fangqiu Fu, Chaoqiang Deng, Zhexu Wen, Zhendong Gao, Yue Zhao, Han Han, Shanbo Zheng, Shengping Wang, Yuan Li, Hong Hu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Fangqiu FuDepartment of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Chaoqiang DengDepartment of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Zhexu WenDepartment of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Zhendong GaoDepartment of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Yue ZhaoDepartment of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Han HanDepartment of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Shanbo ZhengDepartment of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Shengping WangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Yuan LiDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Hong HuDepartment of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Yang ZhangDepartment of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Haiquan ChenDepartment of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune function is a key component affecting tumor progression in patients with cancer. The purpose of this study was to identify the prognostic value of systemic immune-inflammation index (SII) in patients with non-small cell lung cancer (NSCLC) and the differences of its prognostic value in patients with distinct characteristics.

methodsPatients with completely resected NSCLC were reviewed according to the eighth TNM classification of lung cancer. Patients were further categorized into the low- and high-SII groups. Cox proportional hazard analyses were performed to identify the independent prognostic factors.

resultsA total of 3984 patients with NSCLC were enrolled in this study. Kaplan-Meier analyses demonstrated that high SII was associated with worse recurrence-free survival (RFS) (P<0.001) and overall survival (OS) (P<0.001). Cox proportional hazard analyses revealed that SII was an independent risk factor for worse RFS (P=0.038) and OS (P=0.043). Further analyses demonstrated that the prognostic value of SII was observed only in patients with stage I disease (P<0.001), solid nodules (P=0.002), or adenocarcinoma (P<0.001). Sensitivity analyses using multiple imputation and competing risk analyses also confirmed similar results.

conclusionsSII was associated with worse survival independently, and its prognostic role was exhibited solely in NSCLC patients with stage I disease, solid nodules, and adenocarcinoma. This study helped us specify the target population for clinical use of SII.

Indexed as

Non-small cell lung cancer (NSCLC)prognosissystemic immune-inflammation index (SII)

Identifiers

PMID34430354
PMCPMC8350100

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.